3.63
price up icon1.68%   0.06
after-market Handel nachbörslich: 3.65 0.02 +0.55%
loading
Schlusskurs vom Vortag:
$3.57
Offen:
$3.58
24-Stunden-Volumen:
4.62M
Relative Volume:
0.87
Marktkapitalisierung:
$1.03B
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-12.96
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
-1.36%
1M Leistung:
+11.69%
6M Leistung:
+91.05%
1J Leistung:
+278.12%
1-Tages-Spanne:
Value
$3.48
$3.75
1-Wochen-Bereich:
Value
$3.48
$3.76
52-Wochen-Spanne:
Value
$0.91
$4.0758

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
Firmenname
Akebia Therapeutics Inc
Name
Telefon
617-871-2098
Name
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Name
Mitarbeiter
181
Name
Twitter
@akebiatx
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
AKBA's Discussions on Twitter

Vergleichen Sie AKBA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
3.63 1.03B 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
10.36 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.08 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.26 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.42 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.05 20.17B 16.54B -1.64B 749.00M -1.45

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-04 Fortgesetzt H.C. Wainwright Buy
2025-04-28 Eingeleitet Leerink Partners Outperform
2025-04-01 Eingeleitet Jefferies Buy
2023-11-29 Fortgesetzt BTIG Research Buy
2023-08-28 Hochstufung H.C. Wainwright Neutral → Buy
2023-05-31 Hochstufung Piper Sandler Neutral → Overweight
2022-03-31 Herabstufung H.C. Wainwright Buy → Neutral
2022-03-31 Herabstufung Mizuho Buy → Neutral
2022-03-31 Herabstufung Needham Buy → Hold
2022-03-31 Herabstufung Piper Sandler Overweight → Neutral
2021-03-08 Eingeleitet Cantor Fitzgerald Overweight
2021-01-29 Herabstufung JP Morgan Neutral → Underweight
2019-11-14 Bestätigt Needham Buy
2019-08-06 Bestätigt H.C. Wainwright Buy
2019-07-11 Bestätigt H.C. Wainwright Buy
2019-05-02 Eingeleitet JP Morgan Overweight
2019-03-20 Eingeleitet Citigroup Neutral
2018-09-07 Fortgesetzt Morgan Stanley Equal-Weight
2018-08-10 Bestätigt Needham Buy
2018-06-06 Bestätigt H.C. Wainwright Buy
2017-12-19 Eingeleitet Piper Jaffray Overweight
2017-12-07 Eingeleitet BTIG Research Buy
2017-09-15 Eingeleitet RBC Capital Mkts Sector Perform
2017-07-10 Bestätigt H.C. Wainwright Buy
2017-04-27 Bestätigt H.C. Wainwright Buy
2017-04-27 Bestätigt Needham Buy
2016-12-27 Bestätigt H.C. Wainwright Buy
2016-12-20 Bestätigt JMP Securities Mkt Outperform
2016-11-15 Eingeleitet Aegis Capital Buy
2016-09-29 Eingeleitet Brean Capital Buy
2016-03-16 Bestätigt Needham Buy
2016-01-21 Eingeleitet Credit Suisse Neutral
Alle ansehen

Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten

pulisher
Jun 18, 2025

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st

Jun 18, 2025
pulisher
Jun 17, 2025

AVEROA - The Pharma Letter

Jun 17, 2025
pulisher
Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics expands stock incentive plan - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics expands stock incentive plan By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics Approves Stock Plan Amendment at Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 07, 2025

Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 - Seeking Alpha

Jun 07, 2025
pulisher
Jun 07, 2025

Day 7 of Gains Streak for Akebia Therapeutics Stock with 38% Return (vs. 109% YTD) [6/6/2025] - Trefis

Jun 07, 2025
pulisher
Jun 06, 2025

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Akebia Therapeutics at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Jun 06, 2025
pulisher
Jun 05, 2025

Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate UpdatesA... - ADVFN

Jun 05, 2025
pulisher
Jun 04, 2025

Akebia reports mixed results for anemia drug in global study By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia reports mixed results for anemia drug in global study - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA S - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Therapeutics Announces Publication of Pre-specified Analyses on Vadadustat from Global Phase 3 Clinical Program in Journal of the American Society of Nephrology - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Vadadustat U.S. Patient Data from Global Phase 3 Clinical - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia (AKBA) Receives Buy Rating with Promising Outlook for Vaf - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Ther stock soars to 52-week high, hits $3.31 By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Akebia Ther stock soars to 52-week high, hits $3.31 - Investing.com Australia

Jun 03, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Expands Team with Strategic New Hires, Grants $415,000 in Stock Options - Stock Titan

Jun 02, 2025
pulisher
May 28, 2025

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Kidney Disease Leader Akebia Therapeutics Sets Major Investor Presentation at Jefferies Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 28, 2025

Akebia’s patent for Anemia therapy gets fresh blood from Court - BananaIP

May 28, 2025
pulisher
May 27, 2025

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress - Stock Titan

May 27, 2025
pulisher
May 25, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

May 25, 2025
pulisher
May 24, 2025

Northern Trust Corp Has $3.20 Million Stock Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World

May 24, 2025
pulisher
May 20, 2025

Akebia Therapeutics stock soars to 52-week high of $2.91 By Investing.com - Investing.com India

May 20, 2025
pulisher
May 20, 2025

Akebia Therapeutics at H.C. Wainwright Conference: Vafseo’s Strategic Launch By Investing.com - Investing.com Canada

May 20, 2025
pulisher
May 20, 2025

Akebia Therapeutics stock soars to 52-week high of $2.91 - Investing.com Australia

May 20, 2025
pulisher
May 18, 2025

Certain Common Stock of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 18, 2025

Certain Stock Options of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 18, 2025

Certain Rights of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 18, 2025

Certain Warrants of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 16, 2025

Price T Rowe Associates Inc. MD Has $263,000 Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World

May 16, 2025
pulisher
May 15, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Voya Investment Management LLC - Defense World

May 15, 2025
pulisher
May 14, 2025

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - GuruFocus

May 14, 2025

Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$14.72
price up icon 2.01%
$9.34
price up icon 1.74%
$129.40
price up icon 1.09%
$295.22
price up icon 1.48%
drug_manufacturers_specialty_generic RDY
$14.88
price down icon 0.40%
$17.05
price up icon 2.46%
Kapitalisierung:     |  Volumen (24h):